Editor's note

This article was originally published in February 2016 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

PHEIC and the development acceleration

The WHO's declaration of Zika virus disease as a Public Health Emergency of International Concern (PHEIC) on 1 February 2016 fundamentally altered the development landscape for Zika vaccines. Prior to the declaration, Zika had been a known arboviral infection with a relatively benign clinical reputation - most infections were mild and self-limiting, and the virus had attracted minimal commercial vaccine development investment. The association with microcephaly and other neurological complications in infants born to infected mothers, emerging from the Brazilian outbreak data, changed everything.

The vaccine development landscape in early 2016

Multiple institutions and companies were moving rapidly to initiate or accelerate Zika vaccine programmes: the NIH's NIAID was pursuing a DNA vaccine candidate that had already shown promise in animal models; Inovio Pharmaceuticals had its own DNA vaccine platform; Sanofi-Pasteur was exploring dengue vaccine cross-reactivity; and both J&J and Merck were evaluating their viral vector platforms. None had yet reached Phase I in humans, but the urgency of the PHEIC was driving accelerated IND submissions and compressed pre-clinical timelines.

Suspected Microcephaly Cases
>4,000

Suspected microcephaly cases in Brazil linked to the Zika outbreak by early 2016 - the association that elevated Zika from a minor arboviral concern to a global PHEIC

"Zika is testing the development ecosystem's ability to move from scientific curiosity to Phase I trial in months rather than years - the results of that test will inform how we respond to the next unknown pathogen emergency."